Safety and efficacy of topical formulations containing 0·5, 1 and 2% glycopyrronium bromide in patients with primary axillary hyperhidrosis: a randomized, double-blind, placebo-controlled study
Br J Dermatol
.
2020 Jan;182(1):229-231.
doi: 10.1111/bjd.18234.
Epub 2019 Sep 1.
Authors
C Masur
1
,
M Soeberdt
1
,
A Kilic
1
,
U Knie
1
,
C Abels
1
Affiliation
1
Dr. August Wolff GmbH & Co. KG Arzneimittel, Bielefeld, Germany.
PMID:
31218668
DOI:
10.1111/bjd.18234
No abstract available
Publication types
Letter
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
MeSH terms
Axilla
Double-Blind Method
Glycopyrrolate* / adverse effects
Humans
Hyperhidrosis* / drug therapy
Treatment Outcome
Substances
Glycopyrrolate
Grants and funding
Dr. August Wolff GmbH & Co. KG Arzneimittel, Bielefeld, Germany/International